Anti-angiogenic therapy in glioma

A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas

(2011) Teri N. Kreisl et al.   NEURO-ONCOLOGY

Phase I Study of Vandetanib With Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma

(2010) Jan Drappatz et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

(2010) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

(2010) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab

(2010) M. Prados et al.   NEURO-ONCOLOGY

Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: A phase I study

(2010) N. Butowski et al.   NEURO-ONCOLOGY

A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas

(2009) T. N. Kreisl et al.   CLINICAL CANCER RESEARCH

Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms

(2009) Hrvoje Miletic et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas

(2009) Philip H. Gutin et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

(2009) Eudocia C. Quant et al.   NEURO-ONCOLOGY

Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience

(2009) P. L. Nghiemphu et al.   NEUROLOGY

Brain Tumor Imaging in Clinical Trials

(2008) J.W. Henson et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors

(2008) Felix Bokstein et al.   CANCER

Phase II Pilot Study of Bevacizumab in Combination with Temozolomide and Regional Radiation Therapy for Up-Front Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Interim Analysis of Safety and Tolerability

(2008) Albert Lai et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

A Pilot Safety Study of Lenalidomide and Radiotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme

(2008) Jan Drappatz et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan

(2008) R. M. Zuniga et al.   JOURNAL OF NEURO-ONCOLOGY

An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma

(2008) Andrew D. Norden et al.   JOURNAL OF NEURO-ONCOLOGY

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival

(2008) Ashwatha Narayana et al.   JOURNAL OF NEUROSURGERY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY

Response criteria for glioma

(2008) A Gregory Sorensen et al.   Nature clinical practice. Oncology